| ［1］ |
Wang YF, Geng Y, Xu XL. Generalized interstitial granuloma annulare with tuberculosis and cutis laxa: a rare case report. Int J Dermatol Venereol, 2023,6（3）:172⁃174. doi: 10.1097/JD9.000 0000000000060.
|
| ［2］ |
Lukács J, Schliemann S, Elsner P. Treatment of generalized granuloma annulare ⁃ a systematic review［J］. J Eur Acad Dermatol Venereol, 2015,29（8）:1467⁃1480. doi: 10.1111/jdv.12976.
|
| ［3］ |
Barbieri JS, Rosenbach M, Rodriguez O, et al. Association of granuloma annulare with type 2 diabetes, hyperlipidemia, autoimmune disorders, and hematologic malignant neoplasms［J］. JAMA Dermatol, 2021,157（7）:817⁃823. doi: 10.1001/jamadermatol.2021.1805.
|
| ［4］ |
Min MS, Wu J, He H, et al. Granuloma annulare skin profile shows activation of T⁃helper cell type 1, T⁃helper cell type 2, and Janus kinase pathways［J］. J Am Acad Dermatol, 2020,83（1）:63⁃70. doi: 10.1016/j.jaad.2019.12.028.
|
| ［5］ |
Damsky W, Thakral D, McGeary MK, et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare［J］. J Am Acad Dermatol, 2020,82（3）:612⁃621. doi: 10.1016/j.jaad.2019.05.098.
|
| ［6］ |
Wang A, Rahman NT, McGeary MK, et al. Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib［J］. J Allergy Clin Immunol, 2021,147（5）:1795⁃1809. doi: 10.1016/j.jaci.2020.10.012.
|
| ［7］ |
Damsky W, King BA. Treatment of granuloma annulare with tofacitinib 2% ointment［J］. JAAD Case Rep, 2020,6（1）:69⁃71. doi: 10.1016/j.jdcr.2019.10.016.
|
